
Biocon settles eye disease biosimilar dispute with US biotech Regeneron
Bengaluru: Indian drug maker Biocon’s biosimilars arm Biocon Biologics has announced a settlement and license agreement for its eye disease drug Yesafili (aflibercept-jbvf), an interchangeable biosimilar of blockbuster therapy Eylea with its brand owner …